**Product Profile**

**AIVLOSIN® 17%**
(Tylvalosin Medicated Premix) [PR]

**Product Description**
- Antibiotic premix for oral administration in feed to pigs
- Contains 17% tylvalosin, a macrolide antibiotic (as tylvalosin tartrate)

**Formulation**
- Free-flowing granular product.

**Regulatory Status**
- Approved by Health Canada.

**Indication**
- For the treatment of porcine proliferative enteropathy (PPE) associated with *Lawsonia intracellularis* in pigs.

**Dosage / Administration**
- A granulated medicated premix for use in the manufacture of complete medicated feeds for swine.
- Inclusion rate of 42.5 ppm tylvalosin in complete feed administered continuously as the sole ration for 14 consecutive days.
- To prepare 1 tonne of complete medicated feed, thoroughly mix 0.25 kg Aivlosin® 17% with 999.75 kg of complete feed to obtain a medicated feed with tylvalosin concentration of 0.0425% (42.5 g/1000 kg) = 42.5 ppm
- Aivlosin 17% may also be mixed into feed using a micronutrient dispenser.

**Withdrawal Period**
- 0-days (no withdrawal needed).

**Packaging**
- 10-kg paper/laminate bags.

**Storage**
- Store at or below 25°C.

**Expiration Period**
- 3-year shelf-life for unopened bags.

**Key Features**
- The product of choice for endemic ileitis when a treatment program is needed.
- Excellent control of *Lawsonia intracellularis* - works fast to address outbreaks while providing 14 day extended treatment duration that is ideal for subclinical/chronic forms of the disease.
- Achieves maximal tissue levels within hours of administration.
- Free-flowing granular formulation facilitates consistent mixing.
- No withdrawal period (0 days).
- Wide safety margin.
Aivlosin® ADVERSE REACTIONS: other macrolides due to the potential for cross-resistance. Aivlosin® 17% is not indicated for the treatment of Porcine Respiratory Disease (SRD) associated with Lawsonia intracellularis. It is sound clinical practice to base treatment on susceptibility testing of isolates of the bacteria involved in the infection based on abnormal fecal scores, pigs were provided water containing 50 ppm tylvalosin (moderate or severe respiratory score, moderate or severe depression score, or moderate or severe dehydration score) in drinking water for 5 consecutive days. No adverse reactions related to the drug were observed during the trial. Aivlosin 17% contains 170 g/kg tylvalosin (supplied as tylvalosin tartrate) for oral use in medicating complete feed for swine. Aivlosin® 17% contains 170 g/kg tylvalosin (supplied as tylvalosin tartrate) for oral use in medicating complete feed for swine. Tylvalosin has been shown to cause hypersensitivity reactions in laboratory animals; therefore, people with known hypersensitivity to tylvalosin tartrate should avoid contact with this product. When mixing and handling Aivlosin® 17%, direct contact with eyes, skin and mucous membranes should be avoided. Keep out of reach of children. DESCRIPTION: Aivlosin® 17% contains tylvalosin 170 g/kg tylvalosin (supplied as tylvalosin tartrate) for oral use in medicating complete feed for swine. Tylvalosin, the active ingredient in Aivlosin® 17%, is a macrolide antibiotic. INDICATIONS: For the treatment of Porcine Proliferative Enteropathy (PPE) associated with Lawsonia intracellularis in pigs. Tylvalosin should only be used for the treatment of Porcine Proliferative Enteropathy (PPE) following diagnosis of the disease in the herd by a veterinarian. TARGET SPECIES: Pigs. DOSAGE AND ADMINISTRATION: For Feed Manufacturing Use Only. Do not feed undiluted. Aivlosin® 17% must be thoroughly mixed into feeds before use. Thoroughly mix 0.25 kg Aivlosin® 17% with 999.75 kg of complete feed to obtain a medicated feed with tylvalosin concentration of 0.0425% (42.5 g/1000 kg). To aid in the even distribution of drug in the finished feed, add the full amount of Aivlosin® 17% into a small portion of the feed (at least 10 kg per tonne of finished feed) and mix. Blend this mixture into the remainder of the feed and mix thoroughly. Feed as the sole ration for 14 consecutive days. CAUTIONS: Not for use in breeding animals. The effects of tylvalosin on male and female reproductive performance, including pregnancy and lactation, have not been determined. Do not use in feeds containing pelleting binding agents with the exception of Lignosol (4%) and Agri-Colloid (0.3%). Do not use in feeds containing bentonite. Acute cases and severely diseased pigs with reduced food and water intake should be treated with a suitable injectable product. It is sound clinical practice to base treatment on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of target bacteria. Use of the product deviating from the instructions may increase the risk of development and selection of resistant bacteria and decrease the effectiveness of treatment with other macrolides due to the potential for cross-resistance. ADVERSE REACTIONS: No adverse reactions related to the drug were observed during clinical or target animal safety trials.

WARNINGS: No withdrawal period is required when this drug product is used according to the label directions. Tylvalosin has been shown to cause hypersensitivity reactions in laboratory animals; therefore, people with known hypersensitivity to tylvalosin tartrate should avoid contact with this product. When mixing and handling Aivlosin® 17%, direct contact with eyes, skin and mucous membranes should be avoided. Keep out of reach of children. DESCRIPTION: Aivlosin® 17% contains 170 g/kg tylvalosin (supplied as tylvalosin tartrate) for oral use in medicating complete feed for swine. Tylvalosin, the active ingredient in Aivlosin® 17%, is a macrolide antibiotic. INDICATIONS: For the treatment of Porcine Proliferative Enteropathy (PPE) associated with Lawsonia intracellularis in pigs. Tylvalosin should only be used for the treatment of Porcine Proliferative Enteropathy (PPE) following diagnosis of the disease in the herd by a veterinarian. TARGET SPECIES: Pigs. DOSAGE AND ADMINISTRATION: For Feed Manufacturing Use Only. Do not feed undiluted. Aivlosin® 17% must be thoroughly mixed into feeds before use. Thoroughly mix 0.25 kg Aivlosin® 17% with 999.75 kg of complete feed to obtain a medicated feed with tylvalosin concentration of 0.0425% (42.5 g/1000 kg). To aid in the even distribution of drug in the finished feed, add the full amount of Aivlosin® 17% into a small portion of the feed (at least 10 kg per tonne of finished feed) and mix. Blend this mixture into the remainder of the feed and mix thoroughly. Feed as the sole ration for 14 consecutive days. CAUTIONS: Not for use in breeding animals. The effects of tylvalosin on male and female reproductive performance, including pregnancy and lactation, have not been determined. Do not use in feeds containing pelleting binding agents with the exception of Lignosol (4%) and Agri-Colloid (0.3%). Do not use in feeds containing bentonite. Acute cases and severely diseased pigs with reduced food and water intake should be treated with a suitable injectable product. It is sound clinical practice to base treatment on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of target bacteria. Use of the product deviating from the instructions may increase the risk of development and selection of resistant bacteria and decrease the effectiveness of treatment with other macrolides due to the potential for cross-resistance. ADVERSE REACTIONS: No adverse reactions related to the drug were observed during clinical or target animal safety trials.

WARNINGS: No withdrawal period is required when this drug product is used according to the label directions. Tylvalosin has been shown to cause hypersensitivity reactions in laboratory animals; therefore, people with known hypersensitivity to tylvalosin tartrate should avoid contact with this product. When mixing and handling Aivlosin® 17%, direct contact with eyes, skin and mucous membranes should be avoided. Keep out of reach of children. DESCRIPTION: Aivlosin® 17% contains 170 g/kg tylvalosin (supplied as tylvalosin tartrate) for oral use in medicating complete feed for swine. Tylvalosin, the active ingredient in Aivlosin® 17%, is a macrolide antibiotic. INDICATIONS: For the treatment of Porcine Proliferative Enteropathy (PPE) associated with Lawsonia intracellularis in pigs. Tylvalosin should only be used for the treatment of Porcine Proliferative Enteropathy (PPE) following diagnosis of the disease in the herd by a veterinarian. TARGET SPECIES: Pigs. DOSAGE AND ADMINISTRATION: For Feed Manufacturing Use Only. Do not feed undiluted. Aivlosin® 17% must be thoroughly mixed into feeds before use. Thoroughly mix 0.25 kg Aivlosin® 17% with 999.75 kg of complete feed to obtain a medicated feed with tylvalosin concentration of 0.0425% (42.5 g/1000 kg). To aid in the even distribution of drug in the finished feed, add the full amount of Aivlosin® 17% into a small portion of the feed (at least 10 kg per tonne of finished feed) and mix. Blend this mixture into the remainder of the feed and mix thoroughly. Feed as the sole ration for 14 consecutive days. CAUTIONS: Not for use in breeding animals. The effects of tylvalosin on male and female reproductive performance, including pregnancy and lactation, have not been determined. Do not use in feeds containing pelleting binding agents with the exception of Lignosol (4%) and Agri-Colloid (0.3%). Do not use in feeds containing bentonite. Acute cases and severely diseased pigs with reduced food and water intake should be treated with a suitable injectable product. It is sound clinical practice to base treatment on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of target bacteria. Use of the product deviating from the instructions may increase the risk of development and selection of resistant bacteria and decrease the effectiveness of treatment with other macrolides due to the potential for cross-resistance. ADVERSE REACTIONS: No adverse reactions related to the drug were observed during clinical or target animal safety trials.